← Eichor
Condition: Relapsing Remitting Ms Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Relapsing Remitting Ms

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
Phase 4 · 1 location(s) · Northwestern University · NCT07225361Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Phase 3 · 22 location(s) · National Institute of Allergy and Infectious Diseases (NIAID · NCT04047628Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis
Phase 2 · 1 location(s) · Ari Green · NCT07510607Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Phase 3 · 1 location(s) · Amsterdam UMC, location VUmc · NCT05834855"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
Phase N/A · 1 location(s) · University of California, San Francisco · NCT07222618Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS
NA · 1 location(s) · Shirley Ryan AbilityLab · NCT06390930Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT05177523MS-ResearchBiomarkerS
Phase N/A · 1 location(s) · Cedars-Sinai Medical Center · NCT05204459ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS
Phase 4 · 14 location(s) · Novartis Pharmaceuticals · NCT06733922Deuterium Metabolic Imaging in People with Multiple Sclerosis
Phase N/A · 1 location(s) · University of Aarhus · NCT06611280Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study
NA · 2 location(s) · University of Florida · NCT07376772Combined Motor Imagery and Vestibular Rehab for MS
NA · 1 location(s) · Medipol University · NCT07230015Multiple Sclerosis and the Effects of Ketogenic Diet Therapy
NA · 1 location(s) · IRCCS National Neurological Institute "C. Mondino" Foundatio · NCT06715436Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Phase 4 · 6 location(s) · Novartis Pharmaceuticals · NCT04480853Sexual Dysfunction in Women With Multiple Sclerosis (MS)
Phase N/A · 1 location(s) · Ege University · NCT07193823Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy
Phase 1/Phase 2 · 1 location(s) · University of California, San Francisco · NCT05359653Effects of Ublituximab on Motor Functions in Multiple Sclerosis
EARLY_Phase 1 · 2 location(s) · Georgia State University · NCT06629428Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Phase N/A · 1 location(s) · Haukeland University Hospital · NCT06663111Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
NA · 1 location(s) · University of Maryland, Baltimore · NCT06864936Home Based Functional Balance Intervention for Multiple Sclerosis
NA · 1 location(s) · University of Illinois at Chicago · NCT07355387Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
NA · 1 location(s) · Glostrup University Hospital, Copenhagen · NCT07318129Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
Phase N/A · 2 location(s) · Heinrich-Heine University, Duesseldorf · NCT07426991Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis (Switzerland)
Phase N/A · 1 location(s) · University Hospital, Basel, Switzerland · NCT06526364Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Di
NA · 2 location(s) · Centre Hospitalier Universitaire de Nīmes · NCT07292480Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands
Phase N/A · 2 location(s) · Amsterdam UMC, location VUmc · NCT06567197Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
NA · 1 location(s) · IRCCS Centro Neurolesi Bonino Pulejo · NCT07360977
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.